| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-10-21 | Addex Therapeutics (Switzerland) Charcot-Marie-Tooth Association (CMTA) (USA -IL) | ADX71441 | Charcot-Marie-Tooth disease type 1A (CMT1A) | R&D - research | Rare diseases - Genetic diseases - Neurological diseases | Research agreement |
| 2014-10-21 | Sorin (Italy) Respicardia (USA - MN) | remede® System | licensing |
Cardiovascular diseases | Licensing agreement | |
| 2014-10-21 | Karus Therapeutics (UK) | head of clinical development, head of biology | nomination | Cancer - Oncology - Immunological diseases | Nomination | |
| 2014-10-20 | Enanta Pharmaceuticals (USA - MA) Abbvie (USA - IL) | ABT-493 | hepatitis C | Infectious diseases | Exercise of an option agreement | |
| 2014-10-20 | Cubist Pharmaceuticals (USA - MA) | nomination |
Nomination | |||
| 2014-10-20 | Newlink Genetics (USA - IO) Genentech, a member of Roche Group (USA - CA - Switzerland) | NLG919 | development commercialisation |
Cancer - Oncology | Development agreement | |
| 2014-10-16 | Cardiorentis (Switzerland) Roche (Switzerland) | ularitide | acute heart failure | collaboration |
Cardiovascular diseases | Collaboration agreement |
| 2014-10-16 | Moderna Therapeutics (USA - MA) Karolinska Institutet (Sweden) Karolinska University Hospital | drugs using Moderna\'s messenger RNA (mRNA) Therapeutics™ technology | R&D development |
R&D agreement | ||
| 2014-10-16 | Sanofi Pasteur (France) Immune Design (USA - WA) | herpes simplex virus (HSV) immune therapy (HSV-529, G103) | herpes simplex virus (HSV) infections | development |
Infectious diseases | Development agreement |
| 2014-10-16 | AstraZeneca (UK) the University of Cambridge (UK) | collaboration |
Neurodegenerative diseases - Cancer - Oncology | Collaboration agreement | ||
| 2014-10-16 | Pharmacyclics (USA - CA) Roche (Switzerland) | Imbruvica® (ibrutinib) and Gazyva® (obinutuzumab) | non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2014-10-16 | Ceva Santé Animale (France) CNRS (France) VIA Inno (France) | IT Lab | Collaboration |
Veterinary medicine | Collaboration agreement | |
| 2014-10-16 | Portola Pharmaceuticals (USA - CA) Lonza (Switzerland) | andexanet alfa | antidote for patients receiving a Factor Xa inhibitor who suffer a major bleeding episode or who may require emergency surgery | production manufacturing |
Cardiovascular diseases - Hematological diseases | Production agreement |
| 2014-10-15 | Morphosys (Germany) Lanthio Pharma (The Netherlands) | lantipeptides - LanthioPep™ | R&D licensing |
Technology - Services | Licensing agreement | |
| 2014-10-15 | Philips (The Netherlands) hospital Reinier de Graaf (The Netherlands) | health care technologies, maintenance services and planning and consultancy services | collaboration |
Technology - Services | Collaboration agreement | |
| 2014-10-15 | Selecta Biosciences (USA - MA) Sanofi (France) JDRF | Synthetic Vaccine Particle (SVP™) immunotherapy | type 1 diabetes | R&D collaboration |
Metabolic diseases | R&D agreement |
| 2014-10-15 | Horizon Discovery (UK) undisclosed top ten pharma company | profiling of a lead oncology asset | services |
Cancer - Oncology - Technology - Services | Services contract | |
| 2014-10-15 | Santen Pharmaceutical (Japan) | establishment of a new subsidiary in the EU |
Ophtalmological diseases | Establishment of a new subsidiary in the EU | ||
| 2014-10-14 | Bayer (Germany) Compugen (Israel) | antibody-based therapeutics for cancer immunotherapy | collaboration |
Cancer - Oncology | Milestone | |
| 2014-10-14 | Imaxio (France) German Cancer Research Center (DKFZ) (Germany) | IMX313 pro-immunogenic technology | human papillomavirus (HPV) infections | licensing |
Infectious diseases - Cancer - Oncology | Licensing agreement |
